Clinicopathological Predictors of Response to Neoadjuvant Chemotherapy in Locally Advanced Breast Carcinoma: A Retrospective Study
Keywords:
Breast Carcinoma, Breast Carcinoma, Neoadjuvant Chemotherapy, Neoadjuvant Chemotherapy, Treatment Response, Treatment Response, Histological Grade, Histological GradeAbstract
Background: Neoadjuvant chemotherapy (NACT) constitutes a fundamental component in the management of locally advanced breast carcinoma (LABC). The significant heterogeneity observed in treatment response underscores the imperative to identify reliable predictors to guide therapeutic personalization. Objective: This study sought to identify independent clinicopathological predictors of response to NACT in a cohort of patients with LABC. Methods: A retrospective, single-institution observational study was conducted involving 37 female patients with LABC who completed a full course of anthracycline-based NACT. Clinicopathological parameters were extracted from medical records. Pathological response was evaluated post-treatment, and patients were stratified into responders (achieving pathological complete or partial response) and non-responders (exhibiting stable or progressive disease). Univariate analyses and multivariate logistic regression were employed to ascertain independent predictors of treatment response. Results: The overall objective response rate was 72.9%, with a pathological complete response (pCR) rate of 24.3%. Univariate analysis indicated significant associations between treatment response and histological grade (p=0.05) and estrogen receptor (ER) status (p=0.01). Multivariate logistic regression confirmed ER positivity (Adjusted OR = 0.35; 95% CI: 0.08–0.91; p=0.03) and lower histological grade (Grade II vs. III, Adjusted OR = 0.42; 95% CI: 0.11–0.98; p=0.04) as independent predictors of a favourable response. The Ki-67 proliferation index, lymph node status, HER2 status, and chemotherapy regimen were not statistically significant in the multivariate model. Conclusion: This analysis identifies ER-positive status and lower histological grade as independent determinants of a favourable response to NACT in LABC. These findings elucidate the complex interplay between tumor biology and chemosensitivity, contributing to the evolving paradigm of tailored treatment strategies for this patient population
Downloads
References
Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021). Global Carcinoma statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 Carcinomas in 185 countries. CA: a Carcinoma journal for clinicians, 71(3), 209-249.
Britt, K. L., Cuzick, J., & Phillips, K. A. (2020). Key steps for effective breast Carcinoma prevention. Nature Reviews Carcinoma, 20(8), 417-436.
Conti, M., Morciano, F., Bufi, E., D’Angelo, A., Panico, C., Di Paola, V., ... & Manfredi, R. (2023). Surgical planning after neoadjuvant treatment in breast cancer: A multimodality imaging-based approach focused on MRI. Cancers, 15(5), 1439.
Spring, L. M., Fell, G., Arfe, A., Sharma, C., Greenup, R., Reynolds, K. L., ... & Bardia, A. (2020). Pathologic complete response after neoadjuvant chemotherapy and impact on breast Carcinoma recurrence and survival: a comprehensive meta-analysis. Clinical Carcinoma research, 26(12), 2838-2848.
Cortazar, P., Zhang, L., Untch, M., Mehta, K., Costantino, J. P., Wolmark, N., ... & Von Minckwitz, G. (2014). Pathological complete response and long-term clinical benefit in breast Carcinoma: the CTNeoBC pooled analysis. The Lancet, 384(9938), 164-172.
Houssami, N., Macaskill, P., von Minckwitz, G., Marinovich, M. L., & Mamounas, E. (2012). Meta-analysis of the association of breast Carcinoma subtype and pathologic complete response to neoadjuvant chemotherapy. European journal of Carcinoma, 48(18), 3342-3354.
Yeo, S. K., & Guan, J. L. (2017). Breast Carcinoma: multiple subtypes within a tumor?. Trends in Carcinoma, 3(11), 753-760.
Rakha, E. A., El-Sayed, M. E., Lee, A. H., Elston, C. W., Grainge, M. J., Hodi, Z., ... & Ellis, I. O. (2008). Prognostic significance of Nottingham histologic grade in invasive breast carcinoma. Journal of clinical oncology, 26(19), 3153-3158.
Petrelli, F., Viale, G., Cabiddu, M., & Barni, S. (2015). Prognostic value of different cut-off levels of Ki-67 in breast Carcinoma: a systematic review and meta-analysis of 64,196 patients. Breast Carcinoma research and treatment, 153(3), 477-491.
Chen, X., He, C., Han, D., Zhou, M., Wang, Q., Tian, J., ... & Yang, K. (2017). The predictive value of Ki-67 before neoadjuvant chemotherapy for breast Carcinoma: a systematic review and meta-analysis. Future oncology, 13(9), 843.
Colleoni, M., Viale, G., Zahrieh, D., Pruneri, G., Gentilini, O., Veronesi, P., ... & Goldhirsch, A. (2004). Chemotherapy is more effective in patients with breast Carcinoma not expressing steroid hormone receptors: a study of preoperative treatment. Clinical Carcinoma Research, 10(19), 6622-6628.
Kaufmann, M., von Minckwitz, G., Mamounas, E. P., Cameron, D., Carey, L. A., Cristofanilli, M., Denkert, C., Eiermann, W., Gnant, M., Harris, J. R., Karn, T., Liedtke, C., Mauri, D., Rouzier, R., Ruckhäberle, E., Semiglazov, V., Symmans, W. F., Tutt, A., & Pusztai, L. (2020). Recommendations from an international consensus conference on the current status and future of neoadjuvant systemic therapy in primary breast Carcinoma. Annals of Surgical Oncology, *27*(8), 2737–2747.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
Terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
